These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 26202952)

  • 1. Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors.
    Amaravadi RK; Hamilton KE; Ma X; Piao S; Portillo AD; Nathanson KL; Carlino MS; Long GV; Puzanov I; Xu X; Morrissette JJ; Tsai KY; Flaherty KT; Sosman JA; Goodman GR; McArthur GA; Rustgi AK; Metz DC; Schuchter LM; Chapman PB; Sepulveda AR
    Clin Cancer Res; 2015 Dec; 21(23):5215-21. PubMed ID: 26202952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic
    Delord JP; Robert C; Nyakas M; McArthur GA; Kudchakar R; Mahipal A; Yamada Y; Sullivan R; Arance A; Kefford RF; Carlino MS; Hidalgo M; Gomez-Roca C; Michel D; Seroutou A; Aslanis V; Caponigro G; Stuart DD; Moutouh-de Parseval L; Demuth T; Dummer R
    Clin Cancer Res; 2017 Sep; 23(18):5339-5348. PubMed ID: 28611198
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
    Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
    J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.
    Schaper-Gerhardt K; Okoye S; Herbst R; Ulrich J; Terheyden P; Pföhler C; Utikal JS; Kreuter A; Mohr P; Dippel E; Satzger I; Sucker A; Schadendorf D; Ugurel S; Gutzmer R
    Eur J Cancer; 2018 Jan; 88():67-76. PubMed ID: 29195116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
    Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
    Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.
    Schilling B; Sondermann W; Zhao F; Griewank KG; Livingstone E; Sucker A; Zelba H; Weide B; Trefzer U; Wilhelm T; Loquai C; Berking C; Hassel J; Kähler KC; Utikal J; Al Ghazal P; Gutzmer R; Goldinger SM; Zimmer L; Paschen A; Hillen U; Schadendorf D;
    Ann Oncol; 2014 Mar; 25(3):747-753. PubMed ID: 24504444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete remission of metastatic melanoma upon BRAF inhibitor treatment - what happens after discontinuation?
    Tolk H; Satzger I; Mohr P; Zimmer L; Weide B; Schäd S; Gutzmer R
    Melanoma Res; 2015 Aug; 25(4):362-6. PubMed ID: 26061438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
    Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
    Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
    Sibaud V; Lamant L; Maisongrosse V; Delord JP
    Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.
    Kakavand H; Wilmott JS; Menzies AM; Vilain R; Haydu LE; Yearley JH; Thompson JF; Kefford RF; Hersey P; Long GV; Scolyer RA
    Clin Cancer Res; 2015 Jul; 21(14):3140-8. PubMed ID: 25609064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New treatment options for metastatic melanoma].
    Tietze JK; Berking C
    Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1462-7. PubMed ID: 24983194
    [No Abstract]   [Full Text] [Related]  

  • 13. Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy.
    Anforth R; Menzies A; Byth K; Carlos G; Chou S; Sharma R; Scolyer RA; Kefford R; Long GV; Fernandez-Peñas P
    J Am Acad Dermatol; 2015 May; 72(5):809-15.e1. PubMed ID: 25748298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF inhibitor treatment of melanoma causing colonic polyps: An alternative hypothesis.
    Kelleher FC; Callaghan G; Gallagher C; O'Sullivan H
    World J Gastroenterol; 2017 May; 23(17):3022-3029. PubMed ID: 28533659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A high neutrophil to lymphocyte ratio prior to BRAF inhibitor treatment is a predictor of poor progression-free survival in patients with metastatic melanoma.
    Finon A; Zaragoza J; Maillard H; Beneton N; Bens G; Samimi M; Caille A; Machet L
    Eur J Dermatol; 2018 Feb; 28(1):38-43. PubMed ID: 29336315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe?
    Sloot S; Fedorenko IV; Smalley KS; Gibney GT
    Expert Opin Pharmacother; 2014 Apr; 15(5):589-92. PubMed ID: 24456413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.
    Massi D; Brusa D; Merelli B; Falcone C; Xue G; Carobbio A; Nassini R; Baroni G; Tamborini E; Cattaneo L; Audrito V; Deaglio S; Mandalà M
    Ann Oncol; 2015 Sep; 26(9):1980-1987. PubMed ID: 26037795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma.
    Aya F; Fernandez-Martinez A; Gaba L; Victoria I; Tosca M; Pineda E; Gascon P; Prat A; Arance A
    Clin Transl Oncol; 2017 Jan; 19(1):119-124. PubMed ID: 27147251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.
    Zimmer L; Livingstone E; Hillen U; Dömkes S; Becker A; Schadendorf D
    Arch Dermatol; 2012 Mar; 148(3):357-61. PubMed ID: 22250191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.